Oncology
Relapsed or Refractory Hematologic Malignancies
0
Pipeline Programs↗
7
Active Trials↗
9
Companies Involved↗
Relapsed or Refractory Hematologic Malignancies is an early-stage landscape with 0 programs across 9 companies. The most active players are Merck & Co., Gilead, Forma Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
20
clinical trials
Completed6 · 30%
Terminated4 · 20%
Recruiting3 · 15%
Active, not recruiting2 · 10%
Withdrawn2 · 10%
Not yet recruiting2 · 10%
Other1 · 5%
Clinical Trials
Trial Activity
20 trials
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Completed·—·Phase 1·NCT01658319·20 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)